On August 25, 2026, the D.C. Circuit told the FDA it had been reading its own forfeiture statute wrong for
The First Filer Doesn’t Always Keep the 180 Days: The Forfeiture Triggers Nobody Tracks Read Post »
On July 24, 2025, the Acting Director of the U.S. Patent and Trademark Office denied two of Amgen’s three petitions
The Short Answer A courtroom win in Hatch-Waxman litigation only resolves the specific patent claims that went to trial. It
On May 13, 2026, the Federal Circuit closed out a patent fight that had already run for more than six
Zolgensma’s seven-year orphan drug exclusivity expired in May 2026. Novartis has faced this moment for a year without a single
Ranbaxy launched generic Lipitor on November 30, 2011. Pfizer’s exclusivity ended that day. If a payer or brand team modeled
Stop Budgeting for Generic Entry as a Single Date: Multi-Source Entry Happens in Waves Read Post »
USPTO maintenance fees on a single utility patent jump from $2,150 to $4,040 to $8,280 across three fixed windows for
The Three-Year Explosion: Why “File Early, File Often” Bankrupts Small IP Budgets Read Post »
In February, March, and April 2017, twenty-five generic drug companies sent Bristol-Myers Squibb and Pfizer formal notice that they had
On September 12, 2025, a Delaware jury awarded Mallinckrodt Pharmaceuticals roughly $9.5 million against Airgas Healthcare for infringing patents covering
The At-Risk Launch Damages Model Still Runs on 2015 Math Read Post »
Sign in or create a free account to read this DrugPatentWatch article
